- Home
- AUNA vs ERAS Comparison
AUNA vs ERAS Comparison
Compare AUNA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUNA
- ERAS
- Stock Information
- Founded
- AUNA 1989
- ERAS 2018
- Country
- AUNA Luxembourg
- ERAS United States
- Employees
- AUNA N/A
- ERAS N/A
- Industry
- AUNA
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- AUNA
- ERAS Health Care
- Exchange
- AUNA NYSE
- ERAS Nasdaq
- Market Cap
- AUNA 511.4M
- ERAS 410.8M
- IPO Year
- AUNA 2024
- ERAS 2021
- Fundamental
- Price
- AUNA $6.89
- ERAS $1.33
- Analyst Decision
- AUNA Buy
- ERAS Strong Buy
- Analyst Count
- AUNA 1
- ERAS 6
- Target Price
- AUNA $13.50
- ERAS $4.83
- AVG Volume (30 Days)
- AUNA 19.7K
- ERAS 1.3M
- Earning Date
- AUNA 05-20-2025
- ERAS 05-20-2025
- Dividend Yield
- AUNA N/A
- ERAS N/A
- EPS Growth
- AUNA N/A
- ERAS N/A
- EPS
- AUNA 0.43
- ERAS N/A
- Revenue
- AUNA $1,162,931,380.00
- ERAS N/A
- Revenue This Year
- AUNA $5.83
- ERAS N/A
- Revenue Next Year
- AUNA $7.86
- ERAS N/A
- P/E Ratio
- AUNA $15.90
- ERAS N/A
- Revenue Growth
- AUNA 13.16
- ERAS N/A
- 52 Week Low
- AUNA $6.50
- ERAS $1.01
- 52 Week High
- AUNA $9.89
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- AUNA N/A
- ERAS 48.02
- Support Level
- AUNA N/A
- ERAS $1.37
- Resistance Level
- AUNA N/A
- ERAS $1.53
- Average True Range (ATR)
- AUNA 0.00
- ERAS 0.13
- MACD
- AUNA 0.00
- ERAS -0.00
- Stochastic Oscillator
- AUNA 0.00
- ERAS 30.86
About AUNA AUNA S A
Auna SA is a healthcare provider. It operates hospitals and clinics in Mexico, Peru, and Colombia, and provides prepaid healthcare plans in Peru, and dental and vision plans in Mexico. Its network includes several healthcare network facilities, consisting of hospitals, outpatient, prevention, and wellness facilities. The company operates in the following segments; Oncosalud Peru and Healthcare services in Peru, Columbia and Mexico. Key revenue is generated from Peru.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.